Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head

Caroline Bailleux,Jocelyn Gal,Emmanuel Chamorey,Baharia Mograbi,Gérard Milano
DOI: https://doi.org/10.3390/pharmaceutics16020211
IF: 6.525
2024-02-01
Pharmaceutics
Abstract:Artificial intelligence (AI) is progressively spreading through the world of health, particularly in the field of oncology. AI offers new, exciting perspectives in drug development as toxicity and efficacy can be predicted from computer-designed active molecular structures. AI-based in silico clinical trials are still at their inception in oncology but their wider use is eagerly awaited as they should markedly reduce durations and costs. Health authorities cannot neglect this new paradigm in drug development and should take the requisite measures to include AI as a new pillar in conducting clinical research in oncology.
pharmacology & pharmacy
What problem does this paper attempt to address?
The paper aims to explore the application of Artificial Intelligence (AI) in the development of anti-cancer drugs and its impacts. Specifically, the paper attempts to address the following issues: 1. **Advantages and Limitations of AI in Anti-Cancer Drug Development**: - The paper discusses in detail how AI brings significant advancements in drug design, molecular screening, target identification, and other areas. - At the same time, it points out the limitations of AI in predicting protein structures, handling multi-domain proteins, and predicting the impact of mutations on protein structures. 2. **Application of AI in Clinical Trial Design**: - The paper explores how AI can improve the efficiency and quality of clinical trials by enhancing cancer imaging and diagnosis, simplifying patient recruitment, and other means. - It specifically mentions the potential of using AI for in silico clinical trials, which can reduce time and costs while improving the accuracy of trials. 3. **Relationship Between AI and Serendipity**: - The paper notes that many important drug discoveries have been achieved through serendipity rather than rational design. Therefore, the widespread application of AI in drug development may reduce the opportunities for such serendipitous discoveries. - It emphasizes the importance of maintaining scientific creativity and imagination to avoid over-reliance on AI and neglecting human intuition and innovation. 4. **Application of AI in Immunotherapy and Kinase Inhibitor Development**: - The paper discusses how AI can play a role in the development of immunotherapy and kinase inhibitors, particularly in reducing redundant trial designs and optimizing drug combinations. - It proposes specific solutions, such as using in silico trials to optimize clinical trial design. 5. **Future Prospects**: - The paper calls for health authorities to reassess the rules of clinical trials and incorporate AI and in silico methods. - It highlights the potential of AI to reduce drug development costs and speed up the development of new drugs, while also pointing out the need for further validation and standardization. Overall, the paper aims to comprehensively evaluate the role of AI in anti-cancer drug development, including its positive impacts as well as potential challenges and limitations.